Joshua M Corbin
Overview
Explore the profile of Joshua M Corbin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
63
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Corbin J, Georgescu C, Wang L, Wren J, Bieniasz M, Xu C, et al.
Mol Ther Nucleic Acids
. 2023 Aug;
33:257-272.
PMID: 37554515
Blocking androgen receptor signaling is the mainstay of therapy for advanced prostate cancer (PCa). However, acquired resistance to single agents targeting this pathway results in the development of lethal castration-resistant...
2.
Xu C, Kim A, Corbin J, Wang G
Trends Cancer
. 2023 Jun;
9(9):738-751.
PMID: 37349246
Numerous cellular processes occur in the context of condensates, a type of large, membrane-less biomolecular assembly generated through phase separation. These condensates function as a hub of diversified cellular events...
3.
Corbin J, Georgescu C, Wren J, Xu C, Asch A, Ruiz-Echevarria M
Mol Ther Nucleic Acids
. 2021 Apr;
24():337-351.
PMID: 33850637
Resistance to anti-androgen therapy in prostate cancer (PCa) is often driven by genetic and epigenetic aberrations in the androgen receptor (AR) and coregulators that maintain androgen signaling activity. We show...
4.
Georgescu C, Corbin J, Thibivilliers S, Webb Z, Zhao Y, Koster J, et al.
BMC Cancer
. 2019 May;
19(1):423.
PMID: 31060542
Background: The clinical behavior of prostate cancer (PCa) is variable, and while the majority of cases remain indolent, 10% of patients progress to deadly forms of the disease. Current clinical...
5.
Corbin J, Ruiz-Echevarria M
Int J Mol Sci
. 2016 Jul;
17(8.
PMID: 27472325
Cancer cell metabolism differs significantly from the metabolism of non-transformed cells. This altered metabolic reprogramming mediates changes in the uptake and use of nutrients that permit high rates of proliferation,...
6.
Corbin J, Overcash R, Wren J, Coburn A, Tipton G, Ezzell J, et al.
Prostate
. 2015 Sep;
76(1):97-113.
PMID: 26417683
Background: Previous results from our lab indicate a tumor suppressor role for the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) in prostate cancer (PCa). Here,...
7.
Chen X, Corbin J, Tipton G, Yang L, Asch A, Ruiz-Echevarria M
Biochim Biophys Acta
. 2014 Mar;
1843(6):1216-24.
PMID: 24632071
Cell adhesion and migration play important roles in physiological and pathological states, including embryonic development and cancer invasion and metastasis. The type I transmembrane protein with epidermal growth factor and...